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Background: Despite the development of a new class of antiemetics, postoperative nausea and vomiting (PONV) still 
remains a frequent and distressing complication. We compared the prophylactic antiemetic effect of administering 
dexamethasone 5 mg as an adjunct to ramosetron and ondansetron in patients at high-risk for PONV following 
lumbar spinal surgery. 
Methods: In this randomized, double-blind study, 120 female non-smoking patients with intravenous patient-
controlled analgesia (PCA) received ramosetron 0.3 mg plus dexamethasone 5 mg (group R + D) or ondansetron 
4 mg plus dexamethasone 5 mg (group O + D) intravenously. Fentanyl-based PCA was administered for 48 hr 
postoperatively; ramosetron 0.3 mg or ondansetron 12 mg was added to the PCA regimen according to the allocated 
group. The incidence of PONV and rescue antiemetic were assessed for 48 hr postoperatively at 0-6, 6-24, and 24-
48 hr. 
Results: The overall incidence of PONV did not differ between the groups (50% vs. 60%, in groups R + D and O + D, 
respectively). The overall incidence of nausea was similar between groups (47% vs. 60%, in groups R + D and O + D, 
respectively). The overall frequency of vomiting was also similar between groups (8% vs. 12%, in groups R + D and O 
+ D, respectively). The severity of nausea and the overall use of rescue antiemetic were not different between groups.
Conclusions: The antiemetic efficacy of ramosetron plus dexamethasone was similar to that of ondansetron plus 
dexamethasone on preventing PONV in high-risk patients undergoing lumbar spinal surgery.  (Korean J Anesthesiol 
2012; 62: 543-547)
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Introduction
Postoperative nausea and vomiting (PONV) is a frequent 
and distressing condition which undoubtedly exerts adverse 
influences on patients’ satisfaction and recovery as well as 
resource utilization and health care costs [1]. Accordingly, 
effective therapeutic interventions should be sought and 
considered to prevent PONV, especially in patients with 
several risk factors for PONV, such as the female gender, non-
smoking, prior history of motion sickness or PONV, and the 
use of postoperative opioids [2,3]. In patients undergoing 
lumbar spinal surgery, patient-controlled analgesia (PCA) using 
intravenous opioid is a common and effective method with a 
high satisfaction rate for postoperative pain control; however, it 
is associated with a high incidence of PONV, exceeding 60% [4]. 
Considering the multifactorial nature of PONV and the 
evidence suggesting limited efficacy of a single antiemetic 
treatment, combination of antiemetics from different classes 
is more effective in preventing PONV in patients at moderate 
to severe risk [2,5]. 5-hydroxytryptamine receptor 3 (5-HT3) 
antagonists are frequently used, and among these, ramosetron 
is a newly developed 5-HT3 antagonist with higher receptor 
affinity and a longer duration of action than its congeners, such 
as ondansetron and granisetron [6-8]. Dexamethasone has been 
successfully used as an adjunct to 5-HT3 antagonists, resulting in 
enhanced antiemetic efficacy with negligible side effects [9-12]. 
Although ramosetron demonstrated promising results in recent 
studies for preventing PONV compared to ondansetron in high-
risk patients [6,7], the antiemetic efficacies of these two individual 
5-HT3 antagonists with dexamethasone in patients at high risk for 
PONV have not yet been evaluated.
Therefore, we designed this prospective, randomized, 
double-blind study to compare the antiemetic efficacy of ramo-
setron plus dexamethasone for preventing PONV to that of 
ondansetron plus dexamethasone in highly susceptible patients 
receiving intravenous PCA undergoing lumbar spinal surgery 
during the first postoperative 48 hours.
Materials and Methods
After approval of the institutional review board and obtaining 
informed consent from the patients, we studied 120 ASA 
physical status I and II patients aged 20 to 65 years who were 
scheduled for elective lumbar spinal surgery. The inclusion 
criteria were patients who had three predictors according to 
the simplified risk score for PONV by Apfel et al. [3]: female 
gender, non-smoker, and postoperative opioid use. Patients 
were excluded from the study for the following reasons: admini-
stration of antiemetic medication within 24 hr before surgery, 
administration of steroids within 24 hr before surgery or during 
48 hr after surgery, history of gastrointestinal disease, opioid 
dependence, diabetes mellitus, obesity (body mass index ≥ 35 
kg/m2), and impaired renal or hepatic function. 
On the day of surgery, patients were randomly assigned by 
a computer-generated table of random numbers to receive 
ramosetron plus dexamethasone (group R + D) or ondansetron 
plus dexamethasone (group O + D). Upon arrival at the 
operating room, standard monitoring devices were applied. 
Before the induction of anesthesia, dexamethasone 5 mg was 
given intravenously in both groups. Anesthesia was induced 
with 1.5-2.5 mg/kg propofol and 0.5-1 μg/kg remifentanil, and 
tracheal intubation was facilitated with 0.6 mg/kg rocuronium. 
The patients’ lungs were ventilated with a tidal volume of 8-10 
ml/kg, with an I : E ratio of 1 : 2 at a respiratory rate of 8-12 
breaths/min in 50% oxygen with air to maintain normocarbia 
throughout the surgery. Anesthesia was maintained with 
continuous infusion of remifentanil (0.05-0.2 μg/kg/min), 
rocuronium (5-6 μg/kg/min), and sevoflurane (1.8-2%). 
At the end of the surgery (approximately 15 min before 
tracheal extubation), patients received either ramosetron or 
ondansetron according to their allocated group, and intra-
venous PCA commenced. In group R + D patients, ramosetron 
0.3 mg was injected, and 0.3 mg was added to the PCA regimen. 
In group O + D patients, ondansetron 4 mg was injected, and 
12 mg was added to the PCA regimen. Study medications were 
prepared by personnel not involved in this study and presented 
to blinded investigators as identical 2 ml-filled syringes; the 
PCA syringes were also prepared by the same individuals. The 
PCA regimen consisted of fentanyl 25 μg/kg (total volume 
including saline: 100 ml) and was programmed to deliver 2 ml/
hr as the background infusion and 0.5 ml per demand with a 15 
min lockout during the 48 hr postoperative period. 
Nausea was defined as a subjectively unpleasant sensation 
associated with awareness of the urge to vomit. Vomiting was 
defined as a single episode of the forceful expulsion of gastric 
contents through the mouth or as an expulsive movement 
of the stomach muscles without expelled stomach contents. 
Nausea intensity was graded on a scale of 11 points (0 = no 
nausea, 10 = worst possible nausea) using verbal rating scales 
(VRS). A rescue antiemetic, intravenous metoclopramide 10 
mg, was given in response to nausea with a VRS score > 4 at the 
discretion of the attending physicians blinded to the patients’ 
group assignments, with two or more episodes of vomiting. 
When nausea more than 7 on VRS and/or vomiting persisted 
or patients requested more than 2 consecutive boluses of 
metoclopramide, intravenous PCA was stopped for 2 hr. Pain 
intensity scores were measured on a visual analog scale (VAS; 
0 = no pain, 100 = maximal pain) ranging from 0 to 100 mm. A 
patient received ketorolac 30 mg intravenously by request if her 
pain score exceeded 50 mm on VAS.
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The occurrence of the most frequent side effects of the 5-HT3 
antagonists used in conjunction with opioid-based PCA, such 
as headache, dizziness, and drowsiness, were recorded; adverse 
effects associated with dexamethasone use, such as increased 
risk of infection, glucose intolerance, and delayed wound 
healing, were also assessed throughout the study period. 
Sample size estimation was determined based on the ability 
to detect the difference in the incidence of PONV. With 60 
patients in each group, 80% power at an α of 0.05 was required 
to detect a 25% difference in the number of patients with PONV 
up to 48 hr after surgery. This was based on a pilot study of 40 
patients, in which the incidence of PONV was 7 patients (35%) 
receiving ramosetron plus dexamethasone and 12 patients 
(60%) receiving ondansetron plus dexamethasone. Statistical 
analyses were performed with SPSS 18.0 (SPSS Inc., Chicago, 
IL). All data are expressed as mean ± standard deviation (SD) or 
number. Data between the groups were compared using a chi-
square test, Fisher exact test, independent t-test, or the Mann-
Whitney U test, as appropriate. A P value of less than 0.05 was 
considered to be statistically significant.
Results
One hundred twenty-five patients were assessed. Two 
patients treated with steroids within 24 hr before surgery and 
three patients with impaired renal function were excluded. 
Patients’ characteristics, including history of PONV and/or 
motion sickness and operative data were similar between the 
groups. Additionally, no significant differences were observed 
in the amount of anesthetic agents or narcotics used during 
operation between the groups. PCA devices were discontinued 
in 4 patients (7%) of group R + D and in 6 patients (10%) 
of group O + D due to intractable nausea and/or vomiting 
between 24 and 48 hr after surgery (P = 0.509; Table 1).
The incidence of PONV and need for rescue antiemetics were 
not different between groups throughout the study period. The 
overall incidence of nausea was similar between groups R + D 
and O + D (47% vs. 60%, respectively). The overall incidence of 
vomiting was also similar between groups R + D and O + D (8% 
vs. 12%, respectively). The overall use of rescue antiemetic was 
not different between the groups (28% vs. 20%). Nausea severity 
was similar between the groups (Table 2). The median severity 
of nausea in the three time periods was as follows [interquartile 
range (range)]: 0 [0-2.8 (0-10)] vs. 0 [0-2 (0-9)] (P = 0.72); 0 
[0-2 (0-10)] vs. 0 [0-1 (0-10)] (P = 0.98); and 0 [0-0.8 (0-
8)] vs. 0 [0-0 (0-8)] (P = 0.603) in groups R + D and O + D, 
respectively. 
Pain intensity scores were similar between the groups at 0-6 
hr and 24-48 hr after surgery. The total amount of ketorolac for 
rescue analgesia used was not different between group R + D 
and group O + D (Table 3).
Table 1. Patients’ Characteristics and Operative Data
Group R + D
(n = 60)
Group O + D
(n = 60)
Age (yr)
Body mass index (kg/m2)
History of postoperative nausea 
  and vomiting
History of motion sickness
Simplified risk score
    3
    4
Anesthesia time (min)
Operation time (min)
Amount of fentanyl used (μg)
Crystalloids (ml)
IV PCA discontinuation 
51 ± 9
24 ± 3
2 (3)
18 (30)
41 (68)
19 (32)
166 ± 55
124 ± 51
1,370 ± 140
1,025 ± 266
4 (7)
50 ± 10
23 ± 3
4 (7)
15 (25)
43 (72)
17 (28)
171 ± 45
130 ± 41
1,373 ± 121
998 ± 321
6 (10)
Values are mean ± SD or numbers (%). 
Table 2. Incidence of Nausea, Vomiting, and Requirement for Rescue 
Antiemetic Treatment
Group R + D
(n = 60)
Group O + D
(n = 60)
P
Nausea
    Total
    0-6 hr
    6-24 hr
    24-48 hr
Vomiting
    Total
    0-6 hr
    6-24 hr
    24-48 hr
PONV
    Total
    0-6 hr
    6-24 hr
    24-48 hr
Rescue antiemetic
    Total
    0-6 hr
    6-24 hr
    24-48 hr
28 (47)
20 (33)
20 (33)
15 (25)
5 (8)
3 (5)
3 (5)
1 (2)
30 (50)
21 (35)
21 (35)
15 (25)
17 (28)
10 (17)
8 (13)
5 (8)
36 (60)
24 (40)
22 (37)
12 (21)
7 (12)
3 (5)
3 (5)
2 (3)
36 (60)
24 (40)
22 (37)
12 (21)
12 (20)
8 (13)
6 (10)
5 (8)
0.143
0.449
0.702
0.577
0.543
1.0
1.0
0.615
0.271
0.572
0.849
0.577
0.286
0.609
0.57
1.0
Values are numbers (%). 
Table 3. Pain Intensity Scores and Total Rescue Analgesic Doses
Group R + D
(n = 60)
Group O + D
(n = 60)
P
Pain intensity scores
    0-6 h
    6-24 h
    24-48 h
Pain rescue dose (mg)
35 ± 17
35 ± 19
26 ± 16
82 ± 43
39 ± 13
29 ± 12
25 ± 14
72 ± 41
0.174
0.053
0.606
0.192
Values are mean ± SD. 
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No patient withdrew from the study due to adverse events 
from the 5-HT3 antagonists. The most common adverse effects 
were headache, dizziness, and drowsiness; no differences were 
observed in the incidence of these events between the groups 
during the study period (Table 4). No clinically serious adverse 
events attributed to dexamethasone were observed in either 
group.
Discussion
In this prospective, randomized, double-blind study com-
paring the antiemetic efficacy of ramosetron plus dexametha-
sone with that of ondansetron plus dexamethasone in highly 
susceptible patients using fentanyl-based intravenous PCA 
during the 48 hr period after lumbar spinal surgery, we could 
observe that ondansetron plus dexamethasone was as effective 
as ramosetron plus dexamethasone in reducing the incidence 
of PONV and the severity of nausea.
In patients following lumbar spinal surgery, effective post-
operative pain treatment is important to facilitate early rehabili-
tation and improve recovery, thus preventing the development 
of chronic pain syndrome [13]. Although opioid-based 
intravenous PCA is widely used with a high satisfaction rate 
for postoperative pain control, the baseline risk for PONV of 
nonsmoking women receiving opioid-based intravenous PCA 
is high, reaching about 60% [3]. In addition, vomiting may cause 
dehydration, electrolyte imbalance, disruption of the surgical 
repair, and an increase in the perception of pain, resulting in 
delayed recovery [14]. To avoid unnecessary prolongation of the 
hospital stay, it is important not only to reduce pain intensity 
using an adequate PCA regimen but also to prevent intravenous 
PCA-related PONV. Therefore, in patients highly susceptible to 
PONV treated with opioid-based intravenous PCA, multimodal 
antiemetic prophylaxis should be considered rather than 
treating the established PONV [2,5].
A variety of 5-HT3 antagonists with dexamethasone have 
been used for prophylaxis of PONV, and their antiemetic 
efficacies are more beneficial in combination with dexametha-
sone than alone [9-12,15,16]. Dexamethasone, a corticosteroid, 
has antiemetic properties and acts synergistically with 5-HT3 
antagonists. The suggested mechanisms for the improved 
effects of combination therapy are as follows: dexamethasone 
may inhibit stimulation of 5-HT3 receptors by reducing the 
levels of 5-HT in neural tissue by depleting its precursor try-
pto phan and preventing serotonin release in the gut; by inhi-
biting prostaglandin synthesis; and by reducing the ascending 
parasympathetic impulses to the vomiting center by decreasing 
tissue inflammation of the surgical sites [17-19]. The antiemetic 
effect of dexamethasone is similar against both nausea and 
vomiting, which is more pronounced in the late postoperative 
period by its prolonged biological half-life of 36 to 72 hours [17]. 
However, in this study, the addition of dexamethasone with 
both 5-HT3 antagonists eliminated the differences in efficacy 
between ramosetron and ondansetron, which was observed 
when each drug was used alone in previous studies [6,7,20]. 
In several studies, ramosetron 0.3 mg was more effective 
than ondansetron 4 mg for PONV prophylaxis [6,7,21], while 
ramosetron 0.3 mg was as effective as ondanseton 8 mg in 
reducing the incidence of PONV and nausea severity 24 hr after 
gynecological surgery in high-risk patients receiving fentanyl-
based intravenous PCA [20]. In this study, no difference was 
seen in the incidence of PONV between the ramosetron (0.3 + 
0.3 mg) plus dexamethasone and ondansetron (4 + 12 mg) plus 
dexamethasone groups. Since this was a clinical study, we could 
not clarify the pharmacodynamic interactions of these 5-HT3 
antagonists with dexamethasone. All 5-HT3 antagonists have 
a similar mechanism of action; they bind competitively and 
selectively to the 5-HT3 receptor in the chemoreceptor trigger 
zone and the gastrointestinal tract [22]. However, considerable 
differences exist in receptor affinity and pharmacokinetics, 
including the elimination of the half-life between ramosetron 
and ondansetron (5.8 ± 1.2 hr vs. 3.8 ± 1 hr, respectively) [23,24]. 
Although the addition of corticosteroids could theoretically 
obviate the inferiority of the 5-HT3 antagonists, the more potent 
affinity for the 5-HT3 receptor would not lead to more synergistic 
pharmacodynamic results if drugs from different classes 
partially involve common antiemetic mechanisms [17,18,25]. 
To our knowledge, little has been done to compare the efficacy 
of combination therapy with each 5-HT3 antagonist and 
dexamethasone alone, and studies to determine combination 
therapy mechanisms of action need to be performed.
This study has several limitations. Ramosetron was con-
tinuously infused with intravenous PCA by the same methods 
as delivering ondansetron; however, clinical evidence regar-
ding the pharmacokinetic profile of continuous infusion of 
ramosetron is still lacking. Although evidence is available 
on the appropriate dose of dexamethasone as an adjunct to 
prevent intravenous PCA-related PONV, we selected a relatively 
small dose to reduce dexamethasone’s side effects [11,16]. No 
reports of side effects, such as increased infection risk, glucose 
intolerance, delayed wound healing, and adrenal suppression 
associated with the use of a single dose of dexamethasone, were 
Table 4. Side Effects of Antiemetic Drugs
Group R + D
(n = 60)
Group O + D
(n = 60)
P
Headache
Dizziness 
Drowsiness 
8 (13)
10 (17)
4 (7)
3 (5)
14 (23)
2 (3)
0.114
0.361
0.679
Values are numbers (%). 
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noted [17]. In this study, a single dose of 5 mg dexamethasone 
was not related to these adverse effects.
In conclusion, the antiemetic efficacy of ondansetron plus 
dexamethasone was similar to that of ramosetron plus dexame-
thasone in preventing PONV in highly susceptible patients who 
are receiving fentanyl-based intravenous PCA following lumbar 
spinal surgery. 
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